L-carnitine in the treatment of HIV-associated lipodystrophy syndrome

HIV Medicine

Volumn 2, Issue 1, 2001, Pages 59-60

  Mauss, S ^a,b   Schmutz, G ^a  

^a NONE

^b HIV Specialized Practice   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

CARNITINE; CHOLESTEROL; LAMIVUDINE; NEVIRAPINE; PROTEINASE INHIBITOR; STAVUDINE; TRIACYLGLYCEROL;

ADIPOSE TISSUE; ARTICLE; ATROPHY; BODY FAT; CHOLESTEROL BLOOD LEVEL; CLINICAL ARTICLE; CONTROLLED STUDY; DISEASE ASSOCIATION; DISEASE COURSE; DRUG EFFECT; DRUG USE; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; HYPERTROPHY; LIPODYSTROPHY; PILOT STUDY; PRIORITY JOURNAL; SIDE EFFECT; TRIACYLGLYCEROL BLOOD LEVEL;

BODY WEIGHT; CARNITINE; CHOLESTEROL, LDL; HIV WASTING SYNDROME; HUMANS; LIPODYSTROPHY; PAIN MEASUREMENT; PILOT PROJECTS;

EID: 0035198276     PISSN: 14642662     EISSN: None     Source Type: Journal    
DOI: 10.1046/j.1468-1293.2001.00049.x     Document Type: Article

References (9)

1. Effect of L-carnitine on human immunodeficiency virus-1 infection-associated apoptosis: A pilot study
2. Acetyl-L-carnitne administration increases insulin-like growth factor 1 levels in asymptomatic HIV-1-infected subjects: Correlation with its suppressive effect on lymphocyte apoptosis and ceramide generation
3. Acetyl-carnitine deficiency in AIDS patients with neurotoxicity on treatment antiretroviral nucleoside analogues
4. Fat distribution and metabolic changes in patients with HIV infection
5. Diagnosis, prediction, and natural course of HIV-1 protease-inhibitor-associated lipodystrophy, hyperlipidaemia, and diabetes mellitus: A cohort study
6. Risk factors for the HIV-associated lipodystrophy syndrome in patients with homogeneous duration of ART
7. Fat distribution evaluated by computed tomography and metabolic abnormalities in patients undergoing antiretroviral therapy: Preliminary results of the LIPOCO study
8. Contribution of nucleoside analogue reverse transcriptase inhibitors to subcutaneous fat wasting in patients with HIV infection
9. Lipid-lowering effect of L-carnitine in patients with type-IV hyperlipoproteinaemia